For the estimated 2.7 million people in the United States who suffer from obsessive-compulsive disorder (OCD), prescription pharmacological therapy involves the use of several approved therapies (e.g., sertraline [Pfizer’s Zoloft, generics]), as well as off-label therapies from multiple drug classes. Even though the OCD drug market is highly genericized, the heterogenous nature of both the disorder and patients’ response to treatment provides opportunity for branded drugs (e.g., Trintellix [Lundbeck/Takeda]) to be introduced into the treatment paradigm, often as later-line therapies. Our Treatment Algorithms: Claims Data Analysis provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recentlytreated patients.
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.
Markets covered: United States
Real-world data: Longitudinal patient-level claims data analysis
Key companies: Lundbeck, Takeda, Sunovion, Allergan
Key drugs: Bupropion (Wellbutrin, other brands, generics), clomipramine (Anafranil, generics), fluoxetine (Prozac, generics), sertraline (Zoloft, generics), venlafaxine (Effexor, generics)
Key analysis provided: